This article has been updated from a previous version.

Meridian Bioscience said this week that it has submitted its first molecular amplification-based test, the Illumigene C. difficile molecular diagnostic, for 510(k) approval by the US Food and Drug Administration.

Illumigene is based upon loop amplification, or LAMP, technology. According to Meridian, the technique is isothermal and therefore requires no capital equipment purchase, making molecular diagnostic testing possible for any size laboratory.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.